secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001493152-22-035377
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran registers Indian subsidiary, Pharmalectin India, to commercialize ProLectin-M pending CDSCO approval
--------------------------------------------------------------------------------

- Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.
- Subsidiary to sponsor clinical trials and commercialize Bioxytran's products if CDSCO approval is obtained.
- Indian manufacturing plant is FDA-approved; no distributor identified yet.
- Press release and updated corporate presentation issued Dec 14, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/0001493152-22-035377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222035377/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer